Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a Phase 1 trial investigating AB-1002 for the treatment of patients with congestive heart failure at this year’s American Heart Association Scientific Sessions, which are being held in Philadelphia, U.S., from November 11 to 13, 2023.3,4
